Prostate cancer is the most common cancer in men and a leading cause of morbidity and mortality globally. To ensure that men receive an accurate prostate cancer diagnosis, we developed the PRISM App, a web-based self-assessment platform designed for clinicians to increase their confidence in the use of mpMRI before biopsy. The App, which provided participants with a prostate sector map, anonymous patient’s clinical history and mpMRI technical information, was tested by three radiologists of different mpMRI experience. Participants determined the number of lesions that were present in a set of twenty prostate mpMRI images, by marking and describing their location on the map. They were also asked to decide on the radiological classification, using a five-point Likert scale, and record the T-stage. Participants' screening performance was calculated by two sets of measures based on a) expert’s opinion regarding whether a case should be recalled for further investigation or not and b) the known case pathology regarding whether malignancy was present or not. The results showed that two of the participants had specificity scores at ceiling (100%) whereas the third had a specificity score at the level of change (50%), reflecting the small number of benign cases in the case set (n=6). Participants' comments regarding their experience using the App was positive, indicating that the PRISM scheme could be helpful in building confidence in reading mpMRI cases. Further testing with an appropriate number and variety of cases would be a key element in the success of the PRISM App.
[1]
P. Sasieni,et al.
Reply to ‘Comment on Cancer incidence in the United Kingdom: projections to the year 2030'
,
2013,
British Journal of Cancer.
[2]
M. S. Yousefi,et al.
THE INCIDENCE , RISK FACTORS , AND KNOWLEDGE ABOUT THE PROSTATE CANCER THROUGH WORLDWIDE AND IRAN
,
2017
.
[3]
M. Parmar,et al.
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study
,
2018
.
[4]
A. Jemal,et al.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
,
2018,
CA: a cancer journal for clinicians.
[5]
J. Verne,et al.
Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010
,
2015,
BMC Medicine.